Serina Therapeutics (NYSEAMERICAN:SER – Get Free Report) announced its quarterly earnings results on Thursday. The company reported ($0.58) earnings per share for the quarter, FiscalAI reports.
Serina Therapeutics Stock Performance
SER traded down $0.05 during trading on Friday, reaching $1.67. The company had a trading volume of 135,110 shares, compared to its average volume of 3,063,382. Serina Therapeutics has a 12 month low of $1.22 and a 12 month high of $7.92. The company’s fifty day moving average price is $1.93. The stock has a market capitalization of $24.88 million, a P/E ratio of -0.87 and a beta of 1.15.
Insider Activity at Serina Therapeutics
In other news, insider Randall Moreadith sold 39,000 shares of the business’s stock in a transaction on Thursday, March 19th. The shares were sold at an average price of $2.50, for a total value of $97,500.00. The sale was disclosed in a document filed with the SEC, which is accessible through this link. 17.00% of the stock is currently owned by corporate insiders.
Serina Therapeutics Company Profile
Serina Therapeutics, Inc, a biotechnology company, develops drugs to treat neurological diseases and pain. Its lead product candidate is SER 252, a POZ conjugate for the treatment of Parkinson’s disease. The company also develops SER 227 for long-acting pain relief; SER 214 to treat Parkinson’s disease; and SER 228 for the treatment of epilepsy. In addition, it develops POZ technology in lipid nanoparticle delivered ribonucleic acid vaccines for infectious diseases. Serina Therapeutics, Inc was founded in 2006 and is based in Huntsville, Alabama.
Read More
- Five stocks we like better than Serina Therapeutics
- Viking Sails to All-Time Highs—Fundamentals Signal More to Come
- Datavalut Gains Traction: 5 Reasons to Sell Now
- TMC Stock: Why This Pre-Revenue Miner Is Worth Watching
- The Power Grid Is Dying—Is It Time to Buy Its Replacement?
Receive News & Ratings for Serina Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Serina Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
